| Vertex reports 2Q loss | |
| | |
|
BOSTON (AP) _ Vertex Pharmaceuticals Inc. (VRTX) on Wednesday reported a loss of $188.8 million in its second quarter.
The Boston-based company said it had a loss of 78 cents per share. Losses, adjusted for one-time gains and costs, came to 54 cents per share.
The results beat Wall Street expectations. The average estimate of 13 analysts surveyed by Zacks Investment Research was for a loss of 63 cents per share.
The drugmaker posted revenue of $166.1 million in the period, also beating Street forecasts. Eight analysts surveyed by Zacks expected $145.8 million.
Vertex shares have climbed roughly 6 percent since the beginning of the year, while the Standard & Poor's 500 index has risen slightly more than 2 percent. In the final minutes of trading on Wednesday, shares hit $125.48, a rise of 31 percent in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VRTX at http://www.zacks.com/ap/VRTX
_____
Keywords: Vertex Pharmaceuticals, Earnings Report
|
|
| |
ProfileMarket IndicatorsVALUE : Projects & res.Press releasesAnnual reportRISK : Asset profileContact Cpy |
Vertex Pharma is based in United states of america. Vertex Pharma is listed in United States of America. Its market capitalisation is US$ 100.2 billions as of today (€ 93.4 billions). Its stock quote reached its lowest recent point on March 12, 2004 at US$ 10.00, and its highest recent level on May 01, 2024 at US$ 402.14. Vertex Pharma has 249 070 000 shares outstanding. |